National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Naltrexone / bupropion (Mysimba®)

Naltrexone / bupropion (Mysimba®) is indicated, as an adjunct to a reduced-calorie diet and increased physical activity, for the management of weight in adult patients (≥ 18 years) with a BMI of ≥30 kg/m2 (obese) or ≥27 kg/m2 (overweight) in the presence of one or more weight-related co-morbidities.


NCPE Assessment Process Complete
Rapid review received 12/03/2017
Rapid review completed 28/03/2017
Rapid Review outcome A Full pharmacoeconomic assessment is recommended
Full pharmacoeconomic assessment commissioned by HSE 29/03/2017
Pre-submission consultation with applicant 29/05/2017
Submission received from applicant 06/11/2017
Preliminary review sent to applicant 05/01/2018
NCPE assessment re-commenced 01/02/2018
Factual accuracy sent to applicant 24/04/2018
NCPE assessment re-commenced 01/05/2018
NCPE assessment completed 09/05/2018
Full pharmacoeconomic assessment outcome The NCPE recommends that naltrexone/bupropion (Mysimba ®) should not be considered for reimbursement. This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.